Clinical Trials Using Cabozantinib S-malate

Clinical trials are research studies that involve people. The clinical trials on this list are studying Cabozantinib S-malate. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 26-30 of 30

  • Cabozantinib-s-malate in Treating Patients with Previously Treated Non-small Cell Lung Cancer and Brain Metastases

    This phase II trial studies how well cabozantinib-s-malate works in treating patients with previously treated non-small cell lung cancer that has spread to the brain. Cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania

  • Cabozantinib-S-Malate as First-Line Therapy in Treating Patients With Radioiodine-Refractory Thyroid Cancer That is Metastatic or Cannot Be Removed By Surgery

    This phase II clinical trial studies how well cabozantinib-s-malate works as first-line therapy in treating patients with radioiodine-refractory thyroid cancer that has spread to other places in the body or cannot be removed by surgery. Cabozantinib may result in disease response and possibly allow for a prolonged period of response or stabilization of thyroid cancer by blocking some of the enzymes needed for cell growth.
    Location: University of Pennsylvania / Abramson Cancer Center, Philadelphia, Pennsylvania

  • Cabozantinib and Pembrolizumab for the Treatment of Metastatic or Recurrent Gastric or Gastroesophageal Adenocarcinoma

    This trial studies how well cabozantinib and pembrolizumab work in treating patients with gastric or gastroesophageal adenocarcinoma that has spread to other places in the body (metastatic) or come back (recurrent). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib and pembrolizumab may work better than either drug alone in treating metastatic or recurrent gastric or gastroesophageal adenocarcinoma.
    Location: 2 locations

  • Cabozantinib and Pembrolizumab for the Treatment of Stage IIIC-IV Melanoma

    This phase I / II trial studies the best dose of cabozantinib when given together with pembrolizumab and to see how well it works in treating patients with stage IIIC-IV melanoma. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib and pembrolizumab may work better in treating patients with melanoma compared to pembrolizumab alone.
    Location: University of Iowa / Holden Comprehensive Cancer Center, Iowa City, Iowa

  • Cabozantinib S-malate and Nivolumab in Treating Patients with Advanced, Recurrent or Metastatic Endometrial Cancer

    This randomized phase II trial studies how well cabozantinib s-malate and nivolumab work in treating patients with endometrial that has come back or spread to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib and nivolumab may work better in treating endometrial cancer.
    Location: 31 locations